Global Peptide Drug CDMO Market Research Report 2026

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide Drug CDMO Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 APIs and Intermediates
1.2.3 FDF
1.3 Market by Application
1.3.1 Global Peptide Drug CDMO Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Antineoplastic Drugs
1.3.3 Geno-Urinary System and Sex Hormones
1.3.4 Cardiovascular System Drugs
1.3.5 Anti-Infective Drugs
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide Drug CDMO Market Perspective (2021–2032)
2.2 Global Peptide Drug CDMO Growth Trends by Region
2.2.1 Global Peptide Drug CDMO Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Peptide Drug CDMO Historic Market Size by Region (2021–2026)
2.2.3 Peptide Drug CDMO Forecasted Market Size by Region (2027–2032)
2.3 Peptide Drug CDMO Market Dynamics
2.3.1 Peptide Drug CDMO Industry Trends
2.3.2 Peptide Drug CDMO Market Drivers
2.3.3 Peptide Drug CDMO Market Challenges
2.3.4 Peptide Drug CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide Drug CDMO Players by Revenue
3.1.1 Global Top Peptide Drug CDMO Players by Revenue (2021–2026)
3.1.2 Global Peptide Drug CDMO Revenue Market Share by Players (2021–2026)
3.2 Global Top Peptide Drug CDMO Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Peptide Drug CDMO Revenue
3.4 Global Peptide Drug CDMO Market Concentration Ratio
3.4.1 Global Peptide Drug CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide Drug CDMO Revenue in 2025
3.5 Global Key Players of Peptide Drug CDMO Head Offices and Areas Served
3.6 Global Key Players of Peptide Drug CDMO, Products and Applications
3.7 Global Key Players of Peptide Drug CDMO, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Peptide Drug CDMO Breakdown Data by Type
4.1 Global Peptide Drug CDMO Historic Market Size by Type (2021–2026)
4.2 Global Peptide Drug CDMO Forecasted Market Size by Type (2027–2032)
5 Peptide Drug CDMO Breakdown Data by Application
5.1 Global Peptide Drug CDMO Historic Market Size by Application (2021–2026)
5.2 Global Peptide Drug CDMO Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Peptide Drug CDMO Market Size (2021–2032)
6.2 North America Peptide Drug CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Peptide Drug CDMO Market Size by Country (2021–2026)
6.4 North America Peptide Drug CDMO Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peptide Drug CDMO Market Size (2021–2032)
7.2 Europe Peptide Drug CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Peptide Drug CDMO Market Size by Country (2021–2026)
7.4 Europe Peptide Drug CDMO Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Peptide Drug CDMO Market Size (2021–2032)
8.2 Asia-Pacific Peptide Drug CDMO Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Peptide Drug CDMO Market Size by Region (2021–2026)
8.4 Asia-Pacific Peptide Drug CDMO Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Peptide Drug CDMO Market Size (2021–2032)
9.2 Latin America Peptide Drug CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Peptide Drug CDMO Market Size by Country (2021–2026)
9.4 Latin America Peptide Drug CDMO Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide Drug CDMO Market Size (2021–2032)
10.2 Middle East & Africa Peptide Drug CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Peptide Drug CDMO Market Size by Country (2021–2026)
10.4 Middle East & Africa Peptide Drug CDMO Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bachem
11.1.1 Bachem Company Details
11.1.2 Bachem Business Overview
11.1.3 Bachem Peptide Drug CDMO Introduction
11.1.4 Bachem Revenue in Peptide Drug CDMO Business (2021–2026)
11.1.5 Bachem Recent Development
11.2 PolyPeptide
11.2.1 PolyPeptide Company Details
11.2.2 PolyPeptide Business Overview
11.2.3 PolyPeptide Peptide Drug CDMO Introduction
11.2.4 PolyPeptide Revenue in Peptide Drug CDMO Business (2021–2026)
11.2.5 PolyPeptide Recent Development
11.3 CordenPharma
11.3.1 CordenPharma Company Details
11.3.2 CordenPharma Business Overview
11.3.3 CordenPharma Peptide Drug CDMO Introduction
11.3.4 CordenPharma Revenue in Peptide Drug CDMO Business (2021–2026)
11.3.5 CordenPharma Recent Development
11.4 AmbioPharm
11.4.1 AmbioPharm Company Details
11.4.2 AmbioPharm Business Overview
11.4.3 AmbioPharm Peptide Drug CDMO Introduction
11.4.4 AmbioPharm Revenue in Peptide Drug CDMO Business (2021–2026)
11.4.5 AmbioPharm Recent Development
11.5 USV Peptides
11.5.1 USV Peptides Company Details
11.5.2 USV Peptides Business Overview
11.5.3 USV Peptides Peptide Drug CDMO Introduction
11.5.4 USV Peptides Revenue in Peptide Drug CDMO Business (2021–2026)
11.5.5 USV Peptides Recent Development
11.6 Thermofischer
11.6.1 Thermofischer Company Details
11.6.2 Thermofischer Business Overview
11.6.3 Thermofischer Peptide Drug CDMO Introduction
11.6.4 Thermofischer Revenue in Peptide Drug CDMO Business (2021–2026)
11.6.5 Thermofischer Recent Development
11.7 Bio Basic
11.7.1 Bio Basic Company Details
11.7.2 Bio Basic Business Overview
11.7.3 Bio Basic Peptide Drug CDMO Introduction
11.7.4 Bio Basic Revenue in Peptide Drug CDMO Business (2021–2026)
11.7.5 Bio Basic Recent Development
11.8 JPT
11.8.1 JPT Company Details
11.8.2 JPT Business Overview
11.8.3 JPT Peptide Drug CDMO Introduction
11.8.4 JPT Revenue in Peptide Drug CDMO Business (2021–2026)
11.8.5 JPT Recent Development
11.9 Genscript
11.9.1 Genscript Company Details
11.9.2 Genscript Business Overview
11.9.3 Genscript Peptide Drug CDMO Introduction
11.9.4 Genscript Revenue in Peptide Drug CDMO Business (2021–2026)
11.9.5 Genscript Recent Development
11.10 Xinbang Pharma
11.10.1 Xinbang Pharma Company Details
11.10.2 Xinbang Pharma Business Overview
11.10.3 Xinbang Pharma Peptide Drug CDMO Introduction
11.10.4 Xinbang Pharma Revenue in Peptide Drug CDMO Business (2021–2026)
11.10.5 Xinbang Pharma Recent Development
11.11 ScinoPharm
11.11.1 ScinoPharm Company Details
11.11.2 ScinoPharm Business Overview
11.11.3 ScinoPharm Peptide Drug CDMO Introduction
11.11.4 ScinoPharm Revenue in Peptide Drug CDMO Business (2021–2026)
11.11.5 ScinoPharm Recent Development
11.12 SN Biopharm
11.12.1 SN Biopharm Company Details
11.12.2 SN Biopharm Business Overview
11.12.3 SN Biopharm Peptide Drug CDMO Introduction
11.12.4 SN Biopharm Revenue in Peptide Drug CDMO Business (2021–2026)
11.12.5 SN Biopharm Recent Development
11.13 CBL
11.13.1 CBL Company Details
11.13.2 CBL Business Overview
11.13.3 CBL Peptide Drug CDMO Introduction
11.13.4 CBL Revenue in Peptide Drug CDMO Business (2021–2026)
11.13.5 CBL Recent Development
11.14 Piramal Pharma
11.14.1 Piramal Pharma Company Details
11.14.2 Piramal Pharma Business Overview
11.14.3 Piramal Pharma Peptide Drug CDMO Introduction
11.14.4 Piramal Pharma Revenue in Peptide Drug CDMO Business (2021–2026)
11.14.5 Piramal Pharma Recent Development
11.15 CPC Scientific
11.15.1 CPC Scientific Company Details
11.15.2 CPC Scientific Business Overview
11.15.3 CPC Scientific Peptide Drug CDMO Introduction
11.15.4 CPC Scientific Revenue in Peptide Drug CDMO Business (2021–2026)
11.15.5 CPC Scientific Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Peptide Drug CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of APIs and Intermediates
Table 3. Key Players of FDF
Table 4. Global Peptide Drug CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 5. Global Peptide Drug CDMO Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global Peptide Drug CDMO Market Size by Region (US$ Million), 2021–2026
Table 7. Global Peptide Drug CDMO Market Share by Region (2021–2026)
Table 8. Global Peptide Drug CDMO Forecasted Market Size by Region (US$ Million), 2027–2032
Table 9. Global Peptide Drug CDMO Market Share by Region (2027–2032)
Table 10. Peptide Drug CDMO Market Trends
Table 11. Peptide Drug CDMO Market Drivers
Table 12. Peptide Drug CDMO Market Challenges
Table 13. Peptide Drug CDMO Market Restraints
Table 14. Global Peptide Drug CDMO Revenue by Players (US$ Million), 2021–2026
Table 15. Global Peptide Drug CDMO Market Share by Players (2021–2026)
Table 16. Global Top Peptide Drug CDMO Players by Tier (Tier 1, Tier 2, and Tier 3), based on Peptide Drug CDMO Revenue, 2025
Table 17. Ranking of Global Top Peptide Drug CDMO Companies by Revenue (US$ Million) in 2025
Table 18. Global 5 Largest Players Market Share by Peptide Drug CDMO Revenue (CR5 and HHI), 2021–2026
Table 19. Global Key Players of Peptide Drug CDMO, Headquarters and Area Served
Table 20. Global Key Players of Peptide Drug CDMO, Products and Applications
Table 21. Global Key Players of Peptide Drug CDMO, Date of General Availability (GA)
Table 22. Mergers and Acquisitions, Expansion Plans
Table 23. Global Peptide Drug CDMO Market Size by Type (US$ Million), 2021–2026
Table 24. Global Peptide Drug CDMO Revenue Market Share by Type (2021–2026)
Table 25. Global Peptide Drug CDMO Forecasted Market Size by Type (US$ Million), 2027–2032
Table 26. Global Peptide Drug CDMO Revenue Market Share by Type (2027–2032)
Table 27. Global Peptide Drug CDMO Market Size by Application (US$ Million), 2021–2026
Table 28. Global Peptide Drug CDMO Revenue Market Share by Application (2021–2026)
Table 29. Global Peptide Drug CDMO Forecasted Market Size by Application (US$ Million), 2027–2032
Table 30. Global Peptide Drug CDMO Revenue Market Share by Application (2027–2032)
Table 31. North America Peptide Drug CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 32. North America Peptide Drug CDMO Market Size by Country (US$ Million), 2021–2026
Table 33. North America Peptide Drug CDMO Market Size by Country (US$ Million), 2027–2032
Table 34. Europe Peptide Drug CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. Europe Peptide Drug CDMO Market Size by Country (US$ Million), 2021–2026
Table 36. Europe Peptide Drug CDMO Market Size by Country (US$ Million), 2027–2032
Table 37. Asia-Pacific Peptide Drug CDMO Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 38. Asia-Pacific Peptide Drug CDMO Market Size by Region (US$ Million), 2021–2026
Table 39. Asia-Pacific Peptide Drug CDMO Market Size by Region (US$ Million), 2027–2032
Table 40. Latin America Peptide Drug CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 41. Latin America Peptide Drug CDMO Market Size by Country (US$ Million), 2021–2026
Table 42. Latin America Peptide Drug CDMO Market Size by Country (US$ Million), 2027–2032
Table 43. Middle East & Africa Peptide Drug CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Middle East & Africa Peptide Drug CDMO Market Size by Country (US$ Million), 2021–2026
Table 45. Middle East & Africa Peptide Drug CDMO Market Size by Country (US$ Million), 2027–2032
Table 46. Bachem Company Details
Table 47. Bachem Business Overview
Table 48. Bachem Peptide Drug CDMO Product
Table 49. Bachem Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
Table 50. Bachem Recent Development
Table 51. PolyPeptide Company Details
Table 52. PolyPeptide Business Overview
Table 53. PolyPeptide Peptide Drug CDMO Product
Table 54. PolyPeptide Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
Table 55. PolyPeptide Recent Development
Table 56. CordenPharma Company Details
Table 57. CordenPharma Business Overview
Table 58. CordenPharma Peptide Drug CDMO Product
Table 59. CordenPharma Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
Table 60. CordenPharma Recent Development
Table 61. AmbioPharm Company Details
Table 62. AmbioPharm Business Overview
Table 63. AmbioPharm Peptide Drug CDMO Product
Table 64. AmbioPharm Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
Table 65. AmbioPharm Recent Development
Table 66. USV Peptides Company Details
Table 67. USV Peptides Business Overview
Table 68. USV Peptides Peptide Drug CDMO Product
Table 69. USV Peptides Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
Table 70. USV Peptides Recent Development
Table 71. Thermofischer Company Details
Table 72. Thermofischer Business Overview
Table 73. Thermofischer Peptide Drug CDMO Product
Table 74. Thermofischer Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
Table 75. Thermofischer Recent Development
Table 76. Bio Basic Company Details
Table 77. Bio Basic Business Overview
Table 78. Bio Basic Peptide Drug CDMO Product
Table 79. Bio Basic Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
Table 80. Bio Basic Recent Development
Table 81. JPT Company Details
Table 82. JPT Business Overview
Table 83. JPT Peptide Drug CDMO Product
Table 84. JPT Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
Table 85. JPT Recent Development
Table 86. Genscript Company Details
Table 87. Genscript Business Overview
Table 88. Genscript Peptide Drug CDMO Product
Table 89. Genscript Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
Table 90. Genscript Recent Development
Table 91. Xinbang Pharma Company Details
Table 92. Xinbang Pharma Business Overview
Table 93. Xinbang Pharma Peptide Drug CDMO Product
Table 94. Xinbang Pharma Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
Table 95. Xinbang Pharma Recent Development
Table 96. ScinoPharm Company Details
Table 97. ScinoPharm Business Overview
Table 98. ScinoPharm Peptide Drug CDMO Product
Table 99. ScinoPharm Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
Table 100. ScinoPharm Recent Development
Table 101. SN Biopharm Company Details
Table 102. SN Biopharm Business Overview
Table 103. SN Biopharm Peptide Drug CDMO Product
Table 104. SN Biopharm Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
Table 105. SN Biopharm Recent Development
Table 106. CBL Company Details
Table 107. CBL Business Overview
Table 108. CBL Peptide Drug CDMO Product
Table 109. CBL Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
Table 110. CBL Recent Development
Table 111. Piramal Pharma Company Details
Table 112. Piramal Pharma Business Overview
Table 113. Piramal Pharma Peptide Drug CDMO Product
Table 114. Piramal Pharma Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
Table 115. Piramal Pharma Recent Development
Table 116. CPC Scientific Company Details
Table 117. CPC Scientific Business Overview
Table 118. CPC Scientific Peptide Drug CDMO Product
Table 119. CPC Scientific Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
Table 120. CPC Scientific Recent Development
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
Table 124. Authors List of This Report


List of Figures
Figure 1. Peptide Drug CDMO Picture
Figure 2. Global Peptide Drug CDMO Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Peptide Drug CDMO Market Share by Type: 2025 vs 2032
Figure 4. APIs and Intermediates Features
Figure 5. FDF Features
Figure 6. Global Peptide Drug CDMO Market Size by Application (US$ Million), 2021–2032
Figure 7. Global Peptide Drug CDMO Market Share by Application: 2025 vs 2032
Figure 8. Antineoplastic Drugs Case Studies
Figure 9. Geno-Urinary System and Sex Hormones Case Studies
Figure 10. Cardiovascular System Drugs Case Studies
Figure 11. Anti-Infective Drugs Case Studies
Figure 12. Peptide Drug CDMO Report Years Considered
Figure 13. Global Peptide Drug CDMO Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 14. Global Peptide Drug CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global Peptide Drug CDMO Market Share by Region: 2025 vs 2032
Figure 16. Global Peptide Drug CDMO Market Share by Players in 2025
Figure 17. Global Peptide Drug CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 18. The Top 10 and 5 Players Market Share by Peptide Drug CDMO Revenue in 2025
Figure 19. North America Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 20. North America Peptide Drug CDMO Market Share by Country (2021–2032)
Figure 21. United States Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Canada Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Europe Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Europe Peptide Drug CDMO Market Share by Country (2021–2032)
Figure 25. Germany Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. France Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. U.K. Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Italy Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Russia Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Ireland Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Asia-Pacific Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Asia-Pacific Peptide Drug CDMO Market Share by Region (2021–2032)
Figure 33. China Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Japan Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. South Korea Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Southeast Asia Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. India Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Australia & New Zealand Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Latin America Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Latin America Peptide Drug CDMO Market Share by Country (2021–2032)
Figure 41. Mexico Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Brazil Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Middle East & Africa Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Middle East & Africa Peptide Drug CDMO Market Share by Country (2021–2032)
Figure 45. Israel Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Saudi Arabia Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. UAE Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Bachem Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
Figure 49. PolyPeptide Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
Figure 50. CordenPharma Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
Figure 51. AmbioPharm Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
Figure 52. USV Peptides Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
Figure 53. Thermofischer Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
Figure 54. Bio Basic Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
Figure 55. JPT Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
Figure 56. Genscript Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
Figure 57. Xinbang Pharma Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
Figure 58. ScinoPharm Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
Figure 59. SN Biopharm Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
Figure 60. CBL Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
Figure 61. Piramal Pharma Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
Figure 62. CPC Scientific Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit